RxDoctor Payments DataLook up a doctor →

Julie Byrd, MD

Dermatology · Rochester Hills, MINPI 1245254465

Payments from drug & device makers

$38,479in general payments, 2019–2025

Across 1,149 payments — averaging $33.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Sun Pharmaceutical Industries Inc.$5K
  • Johnson & Johnson$3K
  • EPI Health, LLC$2K
  • Galderma Laboratories, L.p.$2K
  • Journey Medical Corporation$2K
  • plus $14K from 36 others

What the payments were for

  • Consulting fees$12,40032%
  • Travel & lodging$7582%
  • Food & beverage$24,43964%
  • Education$8822%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,479 in reported general payments places this provider in the 85th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$796,478
Medicare patients
2,225
Services billed
24,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab24$312,265
Humira PenAdalimumab12$165,428
Dupixent PenDupilumab33$121,355
OpzeluraRuxolitinib Phosphate12$24,073
Betamethasone Dipropionate318$12,000
Doxycycline Ir-DrDoxycycline Monohydrate13$8,554
Clobetasol Propionate159$6,479
Triamcinolone Acetonide372$5,451
Fluorouracil85$5,297
Ketoconazole283$5,079
Doxycycline Hyclate241$4,848
Metronidazole51$3,651
Mometasone Furoate192$3,154
ValacyclovirValacyclovir Hcl124$3,109
Tretinoin32$2,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,710$312,26524 claims
Incyte CorporationOpzelura$506$24,07312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 404 dermatology providers in Michigan.

Other dermatology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →